On Wednesday, Trimeris, a N.C.-based pharmaceutical company and Roche, a Swiss pharmaceutical company stated they are withdrawing a supplemental application with FDA to sell a needle-free injection device for use with the HIV antiretroviral drug Fuzeon.
Trimeris and Roche in July 2005 applied to use Bioject Medical Technologies' Biojector 2000 injection system as a needle-free injection device for use with Fuzeon, which is currently administered with a needle. Fuzeon, a fusion inhibitor, is approved to treat HIV infection in combination with other antiretrovirals. About 10% of eligible U.S. HIV-positive patients were taking Fuzeon in 2005.
Clinical Trials
Clinical trials are experiments that yield useful information to clinicians if a particular treatment is of any value to a patient.
Advertisement
The companies said they decided to withdraw the application after an assessment of the clinical program, as well as a delay in FDA approval because of a request to produce more data, the AP/Houston Chronicle reports.
"While the device has shown potential benefit for some patients, we don't believe it's the ideal alternative delivery option for all treatment-experienced patients," Michelle Zupancic, a vice president at Roche, said, adding, "We continue to review other options for administering Fuzeon,".
![Daily Dose of Antiretroviral Drug Could Save Healthy People from HIV Infection]( "Daily Dose of Antiretroviral Drug Could Save Healthy People from HIV Infection")
Providing healthy people with an antiretroviral drug to protect them against HIV infection could drastically slow the spread of the virus in sub-Saharan Africa, US researchers said Tuesday.
The companies also said in a statement that they believe that "patients who are currently administering Fuzeon with the device through an existing program or clinical trial may continue to do so, provided that the precautions in the current Fuzeon label regarding use with B2000 are followed".
Source: Kaiser Family Foundation
LIN/V
Daily Dose of Antiretroviral Drug Could Save Healthy People from HIV Infection
Providing healthy people with an antiretroviral drug to protect them against HIV infection could drastically slow the spread of the virus in sub-Saharan Africa, US researchers said Tuesday.
Advertisement
The companies also said in a statement that they believe that "patients who are currently administering Fuzeon with the device through an existing program or clinical trial may continue to do so, provided that the precautions in the current Fuzeon label regarding use with B2000 are followed".
Source: Kaiser Family Foundation
LIN/V
Advertisement
Advertisement
|
Advertisement
Latest Drug News
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
Women using hormonal contraception, along with their healthcare providers, should explore alternative pain relief options instead of NSAIDs.
